Compton Capital Management’s GALENA BIOPHARMA INC COM RXII Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-25,000
| Closed | -$10K | – | 152 |
|
|
2016
Q3 | $10K | Buy |
25,000
+15,000
| +150% | +$6K | ﹤0.01% | 146 |
|
|
2016
Q2 | $5K | Sell |
10,000
-10,000
| -50% | -$5K | ﹤0.01% | 143 |
|
|
2016
Q1 | $27K | Buy |
20,000
+5,000
| +33% | +$6.75K | 0.02% | 141 |
|
|
2015
Q4 | $22K | Hold |
15,000
| – | – | 0.01% | 138 |
|
|
2015
Q3 | $24K | Hold |
15,000
| – | – | 0.01% | 131 |
|
|
2015
Q2 | $26K | Hold |
15,000
| – | – | 0.01% | 140 |
|
|
2015
Q1 | $21K | Hold |
15,000
| – | – | 0.01% | 138 |
|
|
2014
Q4 | $23K | Hold |
15,000
| – | – | 0.01% | 143 |
|
|
2014
Q3 | $31K | Hold |
15,000
| – | – | 0.02% | 137 |
|
|
2014
Q2 | $46K | Buy |
+15,000
| New | +$46K | 0.02% | 138 |
|
|
2014
Q1 | – | Sell |
-12,000
| Closed | -$60K | – | 146 |
|
|
2013
Q4 | $60K | Hold |
12,000
| – | – | 0.03% | 137 |
|
|
2013
Q3 | $27K | Hold |
12,000
| – | – | 0.02% | 139 |
|
|
2013
Q2 | $27K | Buy |
+12,000
| New | +$27K | 0.02% | 144 |
|
Compton Capital Management's RXII Position: Q4 2016 in Review
Compton Capital Management sold out of GALENA BIOPHARMA INC COM (RXII) in Q4 2016, closing a stake of 25,000 shares — an estimated $10K sold.
Compton Capital Management first reported a position in RXII in Q2 2013 and held it in 13 quarters. The position peaked at $60K in Q4 2013. 0 funds tracked by Wall St. Rank hold RXII as of Q4 2016.
- Compton Capital Management reported no remaining GALENA BIOPHARMA INC COM position as of Q4 2016 after selling out during the quarter.
- Compton Capital Management sold 25,000 GALENA BIOPHARMA INC COM shares in Q4 2016, an estimated $10K.
- Compton Capital Management first reported a position in GALENA BIOPHARMA INC COM in Q2 2013 and held it in 13 quarters.
- Compton Capital Management's GALENA BIOPHARMA INC COM position peaked at $60K in Q4 2013.
- 0 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q4 2016.
Based on Compton Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.